文献速递淋巴瘤

大B细胞淋巴瘤一线治疗后循环肿瘤DNA可测量残留病变的前瞻性验证

Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.
PubMed 文献 · J Clin Oncol · 2025-12-12

该研究在HOVON-902前瞻性队列中,采用PhasED-Seq检测一线治疗结束(EOT)时循环肿瘤DNA可测量残留病变(ctDNA-MRD),评估其在大B细胞淋巴瘤(LBCL)中的预后价值。结果显示MRD阳性与显著更差的PFS和OS独立相关,且MRD阳性对2年PFS的阳性预测值高于PET阳性,支持将MRD整合至临床疗效评估。

要点

  • EOT时MRD阳性患者3年PFS仅17%,MRD阴性为85%(HR 9.8)。
  • MRD阳性患者3年OS为43%,MRD阴性为92%(HR 7.7)。
  • MRD阳性对2年PFS的PPV为68%,高于PET阳性的56%。

核心结论

  • PhasED-Seq检测的EOT ctDNA-MRD在LBCL中验证为独立预后因素,支持进一步评估其整合至临床疗效评估。

研究设计与样本

  • 前瞻性队列HOVON-902,纳入接受治愈性一线治疗的LBCL患者,共136例可评估PV识别。

主要发现

  • 134/136(99%)患者成功通过组织或血浆识别相位变异(PV)。
  • EOT时83%患者MRD阴性,17%MRD阳性。
  • MRD阳性 vs 阴性:3年PFS 17% vs 85%(HR 9.8,95%CI 5.1-19,P=9.63×10⁻¹²)。
  • MRD阳性 vs 阴性:3年OS 43% vs 92%(HR 7.7,95%CI 3.4-17.4,P=1.27×10⁻⁶)。
  • 多因素分析中,控制IPI和EOT PET-CT后MRD仍为独立预后因素。

关键数值与推荐

  • 在CMR和非CMR亚组中,MRD阳性均与显著更高的复发风险相关。

临床怎么用

  • EOT ctDNA-MRD可辅助PET-CT进行风险分层,MRD阳性提示高复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: End-of-treatment (EOT) response evaluation by positron emission tomography (PET) remains suboptimal in patients with large B-cell lymphoma (LBCL), because of its limited positive predictive value (PPV). Circulating tumor DNA (ctDNA)-based measurable residual disease (MRD) detection offers a minimally invasive approach and may improve prognostication. We prospectively evaluated EOT MRD using phased variant enrichment and detection sequencing (PhasED-Seq) in patients with first-line LBCL. METHODS: Patients were enrolled in the HOVON-902 prospective cohort and received curative-intent first-line treatment. Phased variants (PVs) were identified and tracked using tumor biopsies or pretreatment plasma. The prognostic significance of EOT ctDNA-MRD status in progression-free survival (PFS) and overall survival (OS) was compared with that of the International Prognostic Index (IPI) and EOT PET-computed tomography (CT). RESULTS: PV identification was successful in 134 of 136 (99%) using either tissue or plasma. At EOT, 83% of patients were MRD-negative and 17% of patients were MRD-positive. MRD positivity was strongly associated with inferior outcomes: the 3-year PFS was 17% in MRD-positive versus 85% in MRD-negative patients (hazard ratio [HR], 9.8 [95% CI, 5.1 to 19]; P = 9.63 × 10-12), and the OS was 43% versus 92%, respectively (HR, 7.7 [95% CI, 3.4 to 17.4]; P = 1.27 × 10-6). In multivariate analysis, MRD was an independent prognostic factor when controlling for IPI and EOT PET-CT. MRD positivity had a higher PPV for 2-year PFS than positive PET (68% v 56%, P ≤ .001), whereas negative predictive value was similar between negative MRD and PET (89% v 88%, P = .71). MRD positivity was associated with a significantly higher relapse risk within both complete metabolic response (CMR) and non-CMR subgroups. CONCLUSION: This study validates ultrasensitive ctDNA-MRD detection using PhasED-Seq in a uniformly treated, prospective real-world LBCL cohort. These findings support further evaluation of MRD integration into clinical response assessment.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wang S, Nijland M, Strobbe L, et al. Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma. J Clin Oncol. 2025. PMID: 41385760. doi:10.1200/JCO-25-01712

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。